Introduction: Current models of Alzheimer's disease (AD) progression assume a common pattern and pathology, oversimplifying the heterogeneity of clinical AD.

Methods: We define a syndrome as a unique biomarker progression pattern and develop a lag measure to cluster pre-dementia individuals, reflecting their pathology's multi-dimensionality. The technique uses the time-ordering of events to group individuals based on their position along the disease process and the relative positions of their markers.

Results: An application using Alzheimer's Disease Neuroimaging Initiative (ADNI) data highlights the need for our novel approach to clustering individuals into syndrome groups.

Discussion: Accurately characterizing biomarker curves associated with brain damage requires an initial step that groups individuals on a syndrome basis, accounting for the heterogeneity of underlying pathologies in clinical AD.

Highlights: Developed a novel distance measure and clustering approach for AD biomarker trajectories. Identified distinct subgroups with different biomarker progression patterns in ADNI data. Findings challenge the traditional amyloid cascade hypothesis and suggest AD heterogeneity. Clustering approach accounts for shifts in time and emphasizes progression patterns. Results have implications for AD diagnosis, targeted interventions, and clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.14524DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
12
adni data
12
approach clustering
8
biomarker progression
8
individuals syndrome
8
clustering approach
8
progression patterns
8
unsupervised learning
4
approach
4
learning approach
4

Similar Publications

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is marked by profound neurovascular dysfunction and significant cell-specific alterations in the brain vasculature. Recent advances in high throughput single-cell transcriptomics technology have enabled the study of the human brain vasculature at an unprecedented depth. Additionally, the understudied niche of cerebrovascular cells, such as endothelial and mural cells, and their subtypes have been scrutinized for understanding cellular and transcriptional heterogeneity in AD.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD), a hallmark of age-related cognitive decline, is defined by its unique neuropathology. Metabolic dysregulation, particularly involving glutamine (Gln) metabolism, has emerged as a critical but underexplored aspect of AD pathophysiology, representing a significant gap in our current understanding of the disease.

Methods: To investigate the involvement of GlnMgs in AD, we conducted a comprehensive bioinformatic analysis.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is a prominent neurodegenerative disorder affecting the central nervous system in the elderly. Current understanding of AD primarily centers on the gradual decline in cognitive and memory functions, believed to be influenced by factors including mitochondrial dysfunction, β-amyloid aggregation, and neuroinflammation. Emerging research indicates that neuroinflammation plays a significant role in the development of AD, with the inflammasome potentially mediating inflammatory responses that contribute to neurodegeneration.

View Article and Find Full Text PDF

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is frequently associated with musculoskeletal complications, including sarcopenia and osteoporosis, which substantially impair patient quality of life. Despite these clinical observations, the molecular mechanisms linking AD to bone loss remain insufficiently explored. In this study, we examined the femoral bone microarchitecture and transcriptomic profiles of APP/PS1 transgenic mouse models of AD to elucidate the disease's impact on bone pathology and identify potential gene candidates associated with bone deterioration.

View Article and Find Full Text PDF

Cognitive reserve, a component of resilience, may be conceptualized as the ability to overcome accumulating neuropathology and maintain healthy aging and function. However, research measuring and evaluating it in American Indians is needed. We recruited American Indians from 3 regional centers for longitudinal examinations (2010-13, n = 818; 2017-19, n = 403) including MRI, cognitive, clinical, and questionnaire data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!